Surrozen, Inc. Form 8-K Summary
Business context and reporting period
Surrozen, Inc. filed this Current Report on Form 8-K on August 11, 2021, reporting the closing of the transaction contemplated by the April 15, 2021 Business Combination Agreement among Consonance-HFW Acquisition Corp., Perseverance Merger Sub Inc., and Surrozen, Inc.
The filing identifies Surrozen, Inc. as the registrant and lists its principal executive offices in South San Francisco, California. The company’s prior name was Consonance-HFW Acquisition Corp.
Financial and operating metrics
- The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, transaction proceeds, share counts, or other financial metrics.
- Common stock trades under the symbol SRZN on The Nasdaq Global Market.
- Redeemable warrants trade under the symbol SRZNW on The Nasdaq Capital Market.
Material changes versus the prior comparable period
The material event is the closing of the previously announced business combination. The filing does not provide comparative financial statements or quantify changes in the company’s financial position.
Guidance, outlook, risks, contingencies, and unusual items
- The filing includes a press release announcing the transaction closing and corporate presentation slides that may be used in discussions with investors and analysts.
- No financial guidance, forecast, risk update, contingency, or unusual accounting item is described in the filing text provided.
- The information furnished under Item 7.01, including the press release and corporate presentation, is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings.
Key facts investors should verify
- Review Exhibit 99.1 for the transaction-closing announcement and any details regarding consideration, capitalization, cash proceeds, and transaction adjustments.
- Review Exhibit 99.2 for management’s business description, development programs, milestones, financial expectations, and risk disclosures.
- Confirm the post-closing capital structure, outstanding shares, warrants, lock-ups, and potential dilution in subsequent SEC filings.
- Review subsequent periodic reports for cash runway, operating expenses, financing needs, clinical or operational milestones, and updated risks.